1.2M XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 54,400 | 54,400 | - | - | Performance Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 32,000 | 32,000 | - | - | Performance Stock Option (right to buy) | |
| Christopher Galletta | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 4,560 | 4,560 | - | - | Performance Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,400 | 38,400 | - | - | Performance Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. | 10 Mar 2025 | 17,500 | 63,150 (0%) | 0% | 3.2 | 56,175 | Common Stock |
| Farrell Simon | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 10 Mar 2025 | 76,963 | 81,250 (0%) | 0% | 6.7 | 517,776 | Common Stock |
| Farrell Simon | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.15 per share. | 10 Mar 2025 | 4,350 | 76,900 (0%) | 0% | 7.1 | 31,102 | Common Stock |
| Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,400 | 38,400 | - | - | Performance Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 17,500 | 0 | - | - | Performance Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 63,813 | 11,187 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 31,250 | 18,750 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.91 per share. | 10 Mar 2025 | 63,813 | 126,963 (0%) | 0% | 3.9 | 249,509 | Common Stock |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 10 Mar 2025 | 31,250 | 158,213 (0%) | 0% | 0.5 | 15,969 | Common Stock |
| James V. Cassella | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 257,500 | 257,500 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 811,000 | 811,000 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 116,000 | 116,000 | - | - | Stock Option (right to buy) | |
| Christopher Galletta | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 41,000 | 41,000 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 225,500 | 225,500 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 225,500 | 225,500 | - | - | Stock Option (right to buy) | |
| Christopher Galletta | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 13 Dec 2024 | 15,000 | 19,935 (0%) | 0% | 0.5 | 7,665 | Common Stock |
| Christopher Galletta | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 15,000 | 20,000 | - | - | Stock Option (right to buy) | |
| James V. Cassella | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.04 per share. | 06 Sep 2024 | 1,840 | 213,313 (1%) | 0% | 3.0 | 5,587 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 06 Sep 2024 | 1,840 | 215,153 (1%) | 0% | 1.4 | 2,631 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.03 per share. | 06 Sep 2024 | 4,219 | 213,313 (1%) | 0% | 3.0 | 12,784 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 06 Sep 2024 | 4,219 | 217,532 (1%) | 0% | 1.4 | 6,033 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 1,840 | 0 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 4,219 | 1,840 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 03 Sep 2024 | 3,863 | 217,176 (1%) | 0% | 1.4 | 5,524 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 40,277 | 6,059 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,981 | 46,336 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,863 | 57,317 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.11 per share. | 03 Sep 2024 | 40,277 | 213,313 (1%) | 0% | 3.1 | 125,310 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 03 Sep 2024 | 40,277 | 253,590 (1%) | 0% | 1.4 | 57,596 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.02 per share. | 03 Sep 2024 | 10,981 | 213,313 (1%) | 0% | 3.0 | 33,205 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 03 Sep 2024 | 10,981 | 224,294 (1%) | 0% | 1.4 | 15,703 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.02 per share. | 03 Sep 2024 | 3,863 | 213,313 (1%) | 0% | 3.0 | 11,677 | Common Stock |
| David P. Meeker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 27 Aug 2024 | 4,555 | 357,044 (2%) | 0% | 1.4 | 6,514 | Common Stock |
| David P. Meeker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 4,555 | 0 | - | - | Stock Option (right to buy) | |
| David P. Meeker | Director | Sale of securities on an exchange or to another person at price $ 2.93 per share. | 27 Aug 2024 | 4,555 | 352,489 (1%) | 0% | 2.9 | 13,353 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 19 Aug 2024 | 16,496 | 236,811 (1%) | 0% | 1.4 | 23,589 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 16,496 | 0 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.96 per share. | 19 Aug 2024 | 16,496 | 220,315 (1%) | 0% | 3.0 | 48,883 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 18,660 | 16,496 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.76 per share. | 14 Aug 2024 | 18,660 | 220,315 (1%) | 0% | 2.8 | 51,440 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 14 Aug 2024 | 18,660 | 238,975 (1%) | 0% | 1.4 | 26,684 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.79 per share. | 14 Aug 2024 | 12,745 | 220,315 (1%) | 0% | 2.8 | 35,513 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 14 Aug 2024 | 12,745 | 233,060 (1%) | 0% | 1.4 | 18,225 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.75 per share. | 14 Aug 2024 | 100 | 220,315 (1%) | 0% | 2.8 | 275 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 14 Aug 2024 | 100 | 220,415 (1%) | 0% | 1.4 | 143 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 12,745 | 35,156 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 100 | 47,901 | - | - | Stock Option (right to buy) | |
| Anne M. Vanlent | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Dominick C. Colangelo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| James V. Cassella | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 59,354 | 0 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.55 per share. | 29 May 2024 | 53,368 | 214,433 (1%) | 0% | 2.6 | 136,110 | Common Stock |
| Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 29 May 2024 | 59,354 | 267,801 (1%) | 0% | 2.2 | 129,985 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 16,043 | 48,125 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 22 May 2024 | 4,350 | 53,279 (0%) | 0% | 2.6 | 11,485 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 22 May 2024 | 16,043 | 57,629 (0%) | 0% | 0.5 | 8,198 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 20 May 2024 | 25,037 | 238,350 (1%) | 0% | 2.2 | 54,831 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 25,037 | 33,189 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 2.86 per share. | 20 May 2024 | 25,037 | 213,313 (1%) | 0% | 2.9 | 71,576 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 10 May 2024 | 4,578 | 217,891 (1%) | 0% | 2.2 | 10,026 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 4,578 | 58,226 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 2.90 per share. | 10 May 2024 | 4,578 | 213,313 (1%) | 0% | 2.9 | 13,276 | Common Stock |
| Thomas Sciascia R. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Good Jennifer L. | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 630,000 | 630,000 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Clark David J. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Galletta Christopher | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 28,500 | 28,500 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 11 Aug 2023 | 2,292 | 33,496 (0%) | 0% | 0.5 | 1,171 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.36 per share. | 11 Aug 2023 | 682 | 32,814 (0%) | 0% | 2.4 | 1,610 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,292 | 68,751 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 11 Jul 2023 | 2,292 | 31,891 (0%) | 0% | 0.5 | 1,171 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 2,292 | 71,043 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.34 per share. | 11 Jul 2023 | 687 | 31,204 (0%) | 0% | 2.3 | 1,608 | Common Stock |
| Anne M. Vanlent | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Dominick C. Colangelo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| James V. Cassella | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 6,250 | 50,000 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 20 Jun 2023 | 6,250 | 45,650 (0%) | 0% | 0.5 | 3,194 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 11 May 2023 | 2,291 | 28,480 (0%) | 0% | 0.5 | 1,171 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 2,291 | 75,626 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.89 per share. | 11 May 2023 | 562 | 27,918 (0%) | 0% | 2.9 | 1,624 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.84 per share. | 11 Apr 2023 | 840 | 26,189 (0%) | 0% | 1.8 | 1,545 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 11 Apr 2023 | 2,292 | 27,029 (0%) | 0% | 0.5 | 1,171 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 2,292 | 77,917 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 13 Mar 2023 | 2,291 | 25,629 (0%) | 0% | 0.5 | 1,171 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2023 | 2,291 | 80,209 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 13 Mar 2023 | 892 | 24,737 (0%) | 0% | 1.8 | 1,564 | Common Stock |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2023 | 18,750 | 56,250 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 07 Mar 2023 | 18,750 | 39,400 (0%) | 0% | 0.5 | 9,581 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 375,000 | 375,000 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 187,500 | 187,500 | - | - | Stock Option (right to buy) | |
| Christopher Galletta | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 187,500 | 187,500 | - | - | Stock Option (right to buy) | |
| Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.45 per share. | 13 Feb 2023 | 8,474 | 23,338 (0%) | 0% | 2.4 | 20,761 | Common Stock |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2023 | 27,500 | 82,500 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 13 Feb 2023 | 27,500 | 31,812 (0%) | 0% | 0.5 | 14,053 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 32,000 | 160,000 | - | - | Performance Stock Options (right to buy) | |
| Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 7,500 | 37,500 | - | - | Performance Stock Options (right to buy) | |
| William P. Forbes | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 48,000 | 48,000 | - | - | Performance Stock Options (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 128,000 | 128,000 | - | - | Performance Stock Options (right to buy) | |
| Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 30,000 | 30,000 | - | - | Performance Stock Options (right to buy) | |
| Anne M. Vanlent | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Dominick C. Colangelo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| James V. Cassella | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 1.90 per share. | 11 Apr 2022 | 948,948 | 948,948 (5%) | 5% | 1.9 | 1,803,001 | Common Stock |
| Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 3,000,000 | 3,000,000 | - | - | Pre-Funded Warrants | |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.90 per share. | 11 Apr 2022 | 2,631,578 | 10,421,428 (58%) | 14% | 1.9 | 4,999,998 | Common Stock |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Apr 2022 | 3,000,000 | 3,000,000 | - | - | Pre-Funded Warrants | |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.90 per share. | 11 Apr 2022 | 948,948 | 948,948 (5%) | 5% | 1.9 | 1,803,001 | Common Stock |
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 275,000 | 275,000 | - | - | Stock Option (right to buy) | |
| William P. Forbes | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 137,500 | 137,500 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Christopher Galletta | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Lisa Delfini | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Oct 2021 | 1,851,852 | 1,851,852 | - | - | 7-Year Common Stock Warrant | |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Oct 2021 | 1,851,852 | 1,851,852 | - | - | 3.5-Year Common Stock Warrant | |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Oct 2021 | 1,851,852 | 7,789,850 (43%) | 10% | - | Common Stock | |
| Lisa Delfini | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Anne M. Vanlent | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Dominick C. Colangelo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| James V. Cassella | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Christopher Galletta | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Frank P. Muscolo | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Christopher Seiter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| William P. Forbes | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Dominick C. Colangelo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2020 | 23,684 | 23,684 | - | - | Nonstatutory Stock Option (right to buy) | |
| Anne M. Vanlent | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) | |
| David P. Meeker | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) | |
| Edward T. Mathers | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) | |
| Michael T. Heffernan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) | |
| Ali Behbahani | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.66 per share. | 03 Apr 2020 | 564 | 5,937,998 (33%) | 0% | 2.7 | 1,500 | Common Stock |
| Ali Behbahani | Ten Percent Owner | 03 Apr 2020 | 1,500,000 | 5,938,562 (33%) | 8% | 0.0 | 1,500 | Common Stock | |
| Ali Behbahani | Ten Percent Owner | 03 Apr 2020 | 1,500,000 | 0 | - | - | Call Option (right to buy) | ||
| Frank P. Muscolo | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| James V. Cassella | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 23,684 | 23,684 | - | - | Nonstatutory Stock Option (right to buy) | |
| Jennifer L. Good | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Helena Brett-Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Yann Mazabraud | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Christopher Seiter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Jennifer L. Good | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 310,000 | 310,000 | - | - | Stock Option (right to buy) | |
| Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Yann Mazabraud | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Christopher Seiter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Anne M. Vanlent | None | 09 May 2019 | 107,977 | 0 | - | - | Series A Preferred Stock | ||
| Anne M. Vanlent | None | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 5,000 | 25,983 (0%) | 0% | 10 | 50,000 | Common Stock |
| Anne M. Vanlent | None | 09 May 2019 | 20,983 | 20,983 (0%) | 0% | 0 | Common Stock | ||
| Anne M. Vanlent | None | 09 May 2019 | 47,807 | 0 | - | - | Series C Preferred Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 478,951 | 0 | - | - | Series C Preferred Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 13,271 | 341,239 (1%) | 0% | 0 | Common Stock | ||
| David P. Meeker | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 11,250 | 352,489 (1%) | 0% | 10 | 112,500 | Common Stock |
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 924,880 | 0 | - | - | Series A Preferred Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 192,000 | 0 | - | - | Series A Preferred Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 95,712 | 0 | - | - | Series A Preferred Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 869,565 | 0 | - | - | Series B Preferred Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 300,536 | 300,536 (1%) | 1% | 0 | Common Stock | ||
| David P. Meeker | Director, Ten Percent Owner | 09 May 2019 | 27,432 | 327,968 (1%) | 0% | 0 | Common Stock | ||
| Jennifer L. Good | Director, See Remarks, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 11,250 | 206,204 (1%) | 0% | 10 | 112,500 | Common Stock |
| Jennifer L. Good | Director, See Remarks, Ten Percent Owner | 09 May 2019 | 23,947 | 0 | - | - | Series C Preferred Stock | ||
| Jennifer L. Good | Director, See Remarks, Ten Percent Owner | 09 May 2019 | 18,348 | 194,954 (1%) | 0% | 0 | Common Stock | ||
| Jennifer L. Good | Director, See Remarks, Ten Percent Owner | 09 May 2019 | 109,015 | 0 | - | - | Series A Preferred Stock | ||
| Michael T. Heffernan | None | 09 May 2019 | 3,851 | 3,851 (0%) | 0% | 0 | Common Stock | ||
| Michael T. Heffernan | None | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 2,500 | 6,351 (0%) | 0% | 10 | 25,000 | Common Stock |
| Michael T. Heffernan | None | 09 May 2019 | 34,247 | 0 | - | - | Series C Preferred Stock | ||
| Thomas R. Sciascia | Chief Medical Officer, Ten Percent Owner | 09 May 2019 | 17,118 | 193,724 (1%) | 0% | 0 | Common Stock | ||
| Thomas R. Sciascia | Chief Medical Officer, Ten Percent Owner | 09 May 2019 | 13,410 | 0 | - | - | Series C Preferred Stock | ||
| Thomas R. Sciascia | Chief Medical Officer, Ten Percent Owner | 09 May 2019 | 109,015 | 0 | - | - | Series A Preferred Stock | ||
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 1,000,000 | 2,938,562 (16%) | 5% | 10 | 10,000,000 | Common Stock |
| Ali Behbahani | Ten Percent Owner | 09 May 2019 | 17,099,315 | 0 | - | - | Series C Preferred Stock | ||
| Ali Behbahani | Ten Percent Owner | 09 May 2019 | 1,938,562 | 1,938,562 (10%) | 10% | 0 | Common Stock | ||
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 1,500,000 | 4,438,562 (24%) | 8% | 10 | 15,000,000 | Common Stock |
| Mette Kirstine Agger | None | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 09 May 2019 | 375,000 | 1,151,544 (6%) | 2% | 10 | 3,750,000 | Common Stock |
| Mette Kirstine Agger | None | 09 May 2019 | 776,544 | 776,544 (4%) | 4% | 0 | Common Stock | ||
| Mette Kirstine Agger | None | 09 May 2019 | 6,849,315 | 0 | - | - | Series C Preferred Stock | ||
| Anne M. Vanlent | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) | |
| David P. Meeker | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) | |
| Edward T. Mathers | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) | |
| Michael T. Heffernan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) | |
| Eran Nadav | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) | |
| Mette Kirstine Agger | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) | |
| Annie Mitsak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2019 | 23,684 | 23,684 | - | - | Stock Option (right to buy) |